DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the KILITCH DRUGS INDIA LTD (KILITCH) share price today?

KILITCH DRUGS INDIA LTD (KILITCH) is trading at ₹182.19 on the NSE, down 0.31% on the day. Source: DocStoX.

What is the PE ratio of KILITCH DRUGS INDIA LTD?

KILITCH DRUGS INDIA LTD has a price-to-earnings (PE) ratio of 21.1 in the Healthcare sector.

What is the market capitalisation of KILITCH DRUGS INDIA LTD?

KILITCH DRUGS INDIA LTD has a market capitalisation of approximately ₹635 crore.

KILITCH DRUGS INDIA LTD

KILITCH·NSE·Healthcare

₹182.19▼ -0.56 (-0.31%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹181.15

₹184.85

52W₹117

₹45419%

Open

₹183.00

High

₹184.85

Low

₹181.15

Prev Close

₹182.75

Volume

14.4K

VWAP

₹182.96

Snapshot

Key fundamentals

Market Cap

₹635 Cr

P/E Ratio

21.11Fair

P/B Ratio

2.46

EPS

₹8.63

Book Value

₹80.00

ROE

12.50%Average

ROCE

14.00%Decent

Dividend Yield

0.00%

Debt / Equity

0.32Moderate

Face Value

₹10.00

52W High

₹454.45

52W Low

₹117.25

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹90

▼ 50.7%downside

Trading at ₹182 — 51% above our estimate

BearFair valueBull

₹76₹90₹125

/100

Business quality — Solid

Growth 88Profitability 49Efficiency 15Valuation 78

Plain English

Our view

A steady, established business
Low debt relative to equity
Fundamental red flags (Piotroski 2/9)

Strengths

Low debt relative to equity
Revenue compounding 19% over 3 years
Profit growing 55% a year
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

13% ROE fading to 13% over ~3 yrs, on ₹80 book

₹80

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹125

Analyst target

No analyst coverage

—

Blended fair value₹90

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Revenue compounding 19% over 3 years
Profit growing 55% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

21.1Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

12.5%Average

Above 15% is considered healthy for Indian equities

ROCE

14.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.32Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹635 Cr

P/B

2.46

EPS

₹8.63

Div Yield

—

What changed

Recent changes

Foreign investors+0.1% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 21.1×

Growth

Strong

+19% rev CAGR

Profitability

Healthy

12.5% ROE

Financial health

Comfortable

D/E 0.32

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹26.31L Cr

Trades168

VWAP₹182.96

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+18.8%

+28.1%

10Y

+27.3%

Profit

+55.4%

+49.6%

10Y

—

EPS

+41.0%

+51.3%

10Y

—

Profile

Pros

Company has delivered good profit growth of 60.0% CAGR over last 5 years
Company's median sales growth is 28.4% of last 10 years

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 11.4% over last 3 years.
Company has high debtors of 186 days.
Promoter holding has decreased over last 3 years: -4.48%
Working capital days have increased from 71.9 days to 130 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors bought 0.12 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

64%

Promoter

Promoters

63.8%0.00

Public

29.6%-0.06

FII / FPI

0.1%+0.12

DII

0.0%0.00

Others

6.5%

Total shareholders

12,627+985 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter63.77%

FII0.12%

Public29.64%

Others6.47%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]